de-Jonge H J, Huls G, de-Bont ES. Gene expression profiling in acute myeloid leukaemia[J]. Neth J Med, 2011, 69(4): 167-176. ？ [2]Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity[J]. Hematol Oncol, 2009, 27(4): 171-181.？ [3]Federici L, Falini B. Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization[J]. Protein Sci, 2013, 22(5): 545-556.？ [4]Vardiman J W, Thiele J, Arber D A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes[J]. Blood, 2009, 114(5): 937-951.？ [5]Cheng K, Grisendi S, Clohessy J G, et al. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence[J]. Oncogene, 2007, 26(53): 7391-7400.？ [6]den-Besten W, Kuo M L, Williams R T, et al. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein[J]. Cell Cycle, 2005, 4(11): 1593-1598.？ [7]Bonetti P, Davoli T, Sironi C, et al. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma[J]. J Cell Biol, 2008, 182(1): 19-26.？ [8]Cilloni D, Messa F, Rosso V, et al. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations[J]. Leukemia, 2008, 22(6): 1234-1240.？ [9]Hanada M, Feng J, Hemmings B A. Structure, regulation and function of PKB/AKT--a major therapeutic target[J]. Biochim Biophys Acta, 2004, 1697(1/2): 3-16. [10]Park S, Chapuis N, Tamburini J, et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia[J]. Haematologica, 2010, 95(5): 819-828.？ [11]Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype[J]. N Engl J Med, 2005, 352(3): 254-266.？ [12]Quentmeier H, Martelli MP, Falini B, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin[J]. Leukemia, 2005, 19(10): 1760-1767.？ [13]Lee S B, Xuan-Nguyen T L, Choi J W, et al. Nuclear Akt interacts with B23/NPM and protects it from proteolytic cleavage, enhancing cell survival[J]. Proc Natl Acad Sci U S A, 2008, 105(43): 16584-16589.？ [14]Kwon I S, Lee K H, Choi J W, et al. PI(3,4,5)P3 regulates the ？interaction？ between Akt and B23 in the nucleus[J]. BMB Rep, 2010, 43(2): 127-132.？ [15]Matsuzaki H, Yamamoto T, Kikkawa U. Distinct activation mechanisms of protein kinase B by growth-factor stimulation and heat-shock treatment[J]. Biochemistry, 2004, 43 (14): 4284- 4293.？ [16]Manning B D, Cantley L C. AKT/PKB signaling: navigating downstream[J]. Cell, 2007, 129(7): 1261-1274.？ [17]Sussman M. “AKT”ing lessons for stem cells: regulation of cardiac myocyte and progenitor cell proliferation[J]. Trends Cardiovasc Med, 2007, 17(7): 235-240.？ [18]Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications[J]. Leukemia, 2009, 23(10): 1731-1743.？ [19]Balusu R, Fiskus W, Rao R, et al. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1[J]. Blood, 2011, 118(11): 3096-3106.？ [20]Qin F X, Shao H Y, Chen X C, et al. Knockdown of NPM1 by RNA interference inhibits cells proliferation and induces apoptosis in leukemic cell line[J]. Int J Med Sci, 2011, 8(4): 287-294.
[2]
邵会媛,杨再林,高玉洁,等.核仁磷酸蛋白突变基因表达对NIH3T3细胞增殖和凋亡的影响[J].第三军医大学学报,2010,32(08):783. Shao Huiyuan,Yang Zailin,Gao Yujie,et al.Nucleophosmin mutation promotes cell proliferation and suppresses apoptosis in NIH3T3 cells[J].J Third Mil Med Univ,2010,32(22):783.
